Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs

Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice

(2022) Baoling Ying et al.   CELL

The History of Live Attenuated Centrin Gene-Deleted Leishmania Vaccine Candidates

(2022) Greta Volpedo et al.   Pathogens

Global distribution of treatment resistance gene markers for leishmaniasis

(2022) Samira Salari et al.   JOURNAL OF CLINICAL LABORATORY ANALYSIS

Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases

(2022) Hui-Lee Wong et al.   LANCET

Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study

(2022) Marco Massari et al.   PLOS MEDICINE

Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates

(2022) Sakshi Mohan et al.   PLoS Neglected Tropical Diseases

Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge

(2022) Shanna S. Leventhal et al.   EBioMedicine

Myocarditis or Pericarditis Following the COVID-19 Vaccination in Adolescents: A Systematic Review

(2022) Minglong Li et al.   Vaccines

Memory CD8+ T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination

(2022) Nadia Brasu et al.   NATURE IMMUNOLOGY

T cell immunity to COVID-19 vaccines

(2022) E. John Wherry et al.   SCIENCE

Characterization of a new Leishmania major strain for use in a controlled human infection model

(2021) Helen Ashwin et al.   Nature Communications

Leishmania eukaryotic elongation Factor-1 beta protein is immunogenic and induces parasitological protection in mice against Leishmania infantum infection

(2021) Thaís T.O. Santos et al.   MICROBIAL PATHOGENESIS

An Update on Self-Amplifying mRNA Vaccine Development

(2021) Anna K. Blakney et al.   Vaccines

Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan

(2021) Brima M. Younis et al.   MOLECULAR THERAPY

Intranasal immunization with chitosan microparticles enhances lack-dna vaccine protection and induces specific long-lasting immunity against visceral leishmaniasis

(2021) Daniel Claudio Oliveira Gomes et al.   MICROBES AND INFECTION

The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach

(2021) Matthew Greenhawt et al.   Journal of Allergy and Clinical Immunology-In Practice

Overcoming roadblocks in the development of vaccines for leishmaniasis

(2021) Paul M. Kaye et al.   Expert Review of Vaccines

Vaccines against leishmaniasis: using controlled human infection models to accelerate development

(2021) Vivak Parkash et al.   Expert Review of Vaccines

Multifunctional, TNF-α and IFN-γ-Secreting CD4 and CD8 T Cells and CD8High T Cells Are Associated With the Cure of Human Visceral Leishmaniasis

(2021) Lorranny Santana Rodrigues et al.   Frontiers in Immunology

A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics

(2020) Marijke C. C. Langenberg et al.   NATURE MEDICINE

Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure

(2020) Nir Eyal et al.   JOURNAL OF INFECTIOUS DISEASES

Ethics of controlled human infection to address COVID-19

(2020) Seema K. Shah et al.   SCIENCE

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

(2020) Kizzmekia S. Corbett et al.   NATURE

An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates

(2020) Jesse H. Erasmus et al.   Science Translational Medicine

A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing

(2020) Wen-Wei Zhang et al.   Nature Communications

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery

(2019) Piotr S. Kowalski et al.   MOLECULAR THERAPY

“Running the Gauntlet”: Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a “Call to Action”

(2019) Maria Elena Bottazzi et al.   Human Vaccines & Immunotherapeutics

How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?

(2019) Birgitte K. Giersing et al.   VACCINE

Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections

(2019) Leroy Versteeg et al.   Vaccines

Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis

(2019) Beatriz Coutinho De Oliveira et al.   Human Vaccines & Immunotherapeutics

Experimental infection of human volunteers

(2018) Meta Roestenberg et al.   LANCET INFECTIOUS DISEASES

Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses

(2018) Annette B. Vogel et al.   MOLECULAR THERAPY

Therapeutic vaccine of killed Leishmania amazonensis plus saponin reduced parasite burden in dogs naturally infected with Leishmania infantum

(2018) Kelvinson Fernandes Viana et al.   VETERINARY PARASITOLOGY

Randomized, controlled, double-blinded field trial to assess Leishmania vaccine effectiveness as immunotherapy for canine leishmaniosis

(2018) Angela Toepp et al.   VACCINE

Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against Leishmania donovani

(2018) Malcolm S. Duthie et al.   Frontiers in Immunology

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

(2017) Norbert Pardi et al.   NATURE

Plasmodium vivax Controlled Human Malaria Infection – Progress and Prospects

(2017) Ruth O. Payne et al.   TRENDS IN PARASITOLOGY

A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH

(2017) Mohamed Osman et al.   PLoS Neglected Tropical Diseases

Nasal IgA Provides Protection against Human Influenza Challenge in Volunteers with Low Serum Influenza Antibody Titre

(2017) Victoria M. W. Gould et al.   Frontiers in Microbiology

A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden

(2017) Bruno Mendes Roatt et al.   Frontiers in Immunology

A defined subunit vaccine that protects against vector-borne visceral leishmaniasis

(2017) Malcolm S. Duthie et al.   npj Vaccines

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model

(2016) Beth D. Kirkpatrick et al.   Science Translational Medicine

Recovery of antigen-specific T cell responses from dogs infected with Leishmania ( L .) infantum by use of vaccine associated TLR-agonist adjuvant

(2016) Robert G. Schaut et al.   VACCINE

Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin

(2015) Michela Brazzoli et al.   JOURNAL OF VIROLOGY

Role of CD8+ T cells in protection against Leishmania donovani infection in healed Visceral Leishmaniasis individuals

(2014) Himanshu Kaushal et al.   BMC INFECTIOUS DISEASES

Self-replicating alphavirus RNA vaccines

(2014) Karl Ljungberg et al.   Expert Review of Vaccines

Programmed Death 1-Mediated T Cell Exhaustion during Visceral Leishmaniasis Impairs Phagocyte Function

(2013) K. J. Esch et al.   JOURNAL OF IMMUNOLOGY

CD8 T Cell Exhaustion in Human Visceral Leishmaniasis

(2013) Shalini Gautam et al.   JOURNAL OF INFECTIOUS DISEASES

Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice

(2013) Armin Hekele et al.   Emerging Microbes & Infections

Pseudoinfectious Venezuelan Equine Encephalitis Virus: a New Means of Alphavirus Attenuation

(2012) S. Atasheva et al.   JOURNAL OF VIROLOGY

ChAd63-MVA–vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans

(2012) Susanne H Sheehy et al.   MOLECULAR THERAPY

T Helper1/T Helper2 Cells and Resistance/Susceptibility to Leishmania Infection: Is This Paradigm Still Relevant?

(2012) James Alexander et al.   Frontiers in Immunology

Developments in the treatment of visceral leishmaniasis

(2009) Margriet Leontine den Boer et al.   EXPERT OPINION ON EMERGING DRUGS

Optimized subunit vaccine protects against experimental leishmaniasis

(2009) Sylvie Bertholet et al.   VACCINE

Nonviral Vectors for Gene Delivery

(2008) Meredith A. Mintzer et al.   CHEMICAL REVIEWS

Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis

(2008) Shraddha Kumari et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-110f®+MPL-SE® vaccine to treat canine visceral leishmaniasis

(2008) Jorge Miret et al.   VACCINE